Biological E, a vaccine and pharmaceutical company based in India, announced today that the World Health Organization has prequalified its novel oral poliovirus type 2 (nOPV2) vaccine, a next-generation vaccine for battling circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks.
The company said the live attenuated oral vaccine has improved genetic stability and has a decreased chance of seeding new outbreaks in low-immunity settings compared to the Sabin poliovirus type 2 vaccine. It added that real-world deployment in outbreak regions suggests that it can successfully reduce the incidence of cVDPV2 outbreaks.
Ability to produce 500 million doses a year
Biological E is making the vaccine in collaboration with Indonesia-based PT Bio Farma, which is the first manufacturer of the nOPV2 vaccine, which the WHO prequalified in January. The collaboration and support for production came from the Bill and Melinda Gates Foundation.
Biological E said its manufacturing facilities can produce more than 500 million doses of the vaccine each year. Indian regulators have already cleared the vaccine for export purposes.
Infections involving circulating vaccine-derived polioviruses are rare, resulting from mutations that can occur when the virus spreads among unvaccinated groups. Cases have increased in recent years owing to low immunization rates in certain settings.